Stifel analyst Jonathan Block lowered the firm’s price target on Nyxoah (NYXH) to $8 from $10 and keeps a Buy rating on the shares. The firm’s checks suggest the Q1 reimbursement environment weighed on HGNS volumes, says the analyst, who expects these issues to impact Q1 results and takes a more conservative 2026 view.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NYXH:
- Nyxoah’s Earnings Call Shows Rapid Growth, Rising Risks
- Nyxoah price target lowered to $4.62 from $5.87 at Baird
- Nyxoah Discloses Taub Group’s 10.14% Stake After Threshold Crossing
- Nyxoah price target lowered to $10 from $11 at Stifel
- Nyxoah Leverages First Full U.S. Sales Quarter to Power Triple-Digit 2025 Revenue Growth